Search Results

You are looking at 1 - 10 of 55 items for :

  • "nilotinib" x
Clear All
Full access

Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz and Meir Wetzler

diagnosed CP-CML. 22 Follow-up is ongoing to evaluate whether the short-term deeper molecular response will translate into improved long-term outcomes. Nilotinib Nilotinib is an orally available, highly selective inhibitor of BCR-ABL tyrosine kinase that is

Full access

Paul J. Shami

, nilotinib, and dasatinib, based on a review Describe the case for the use of imatinib in first-line therapy of CML, based on a review Describe the case for the use of dasatinib or nilotinib in first-line therapy of CML, based on a review

Full access

Jorge Cortes, Clara Chen, Michael Mauro, Neela Kumar, Catherine Davis and Stuart L. Goldberg

Introduction: Dosing patterns of nilotinib (NIL) in chronic phase chronic myelogenous leukemia (CP-CML) patients (Pts) have not been well documented outside of clinical trials. SIMPLICITY (NCT01244750) is an ongoing observational study exploring

Full access

Stephen Harnicar

intolerance, dasatinib (Sprycel) and nilotinib (Tasigna) can now be used in front-line therapy because of results of 2 different trials. Dasatinib was compared with imatinib first-line and after a minimum follow-up of 12 months; the rates of confirmed CCyR

Full access

Susan O'Brien, Camille N. Abboud, Mojtaba Akhtari, Jessica Altman, Ellin Berman, Daniel J. DeAngelo, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Vishnu V.B. Reddy, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Meir Wetzler and Furhan Yunus

imatinib at 400 mg (43%) in patients with newly diagnosed CP-CML. 55 Follow-up is ongoing to evaluate whether the short-term deeper molecular response will translate into improved long-term outcomes. Nilotinib Nilotinib is a new, orally available

Full access

Susan O'Brien, Ellin Berman, Hossein Borghaei, Daniel J. DeAngelo, Marcel P. Devetten, Steven Devine, Harry P. Erba, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Tariq Mughal, Javier Pinilla-Ibarz, Jerald P. Radich, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Martin S. Tallman, Moshe Talpaz and Meir Wetzler

. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [abstract] . Blood 2008 ; 112 : Abstract 182 . 37 Kantarjian H Giles F Wunderle L . Nilotinib in imatinib

Full access

Ellin Berman

nilotinib based on results of phase I and II trials that showed greater than 70% major cytogenetic response rates in heavily pretreated patients. 1 , 2 Ponatinib was also approved for patients with the T315I BCR-ABL1 mutation, with similar response rates

Full access

Jerald P. Radich

include imatinib, nilotinib, and dasatinib. 2 - 5 These second-generation agents tend to be preferred over higher doses of imatinib, as that approach is more toxic, explained Dr. Radich. The data supporting imatinib for chronic-phase CML came from the

Full access

Susan O’Brien, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Daniel J. DeAngelo, Michael Deininger, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O. Moore, Arnel Pallera, Javier Pinilla-Ibarz, Vishnu VB. Reddy, Neil P. Shah, B. Douglas Smith, David S. Snyder, Meir Wetzler, Kristina Gregory and Hema Sundar

) therapy (with imatinib, dasatinib, or nilotinib) is the standard first-line treatment for patients with newly diagnosed chronic-phase CML (see CML-1, page 1329). 3 - 5 Early molecular response to first-line TKI therapy is emerging as an effective

Full access

Matthew P. Banegas, Donna R. Rivera, Maureen C. O’Keeffe-Rosetti, Nikki M. Carroll, Pamala A. Pawloski, David C. Tabano, Mara M. Epstein, Kai Yeung, Mark C. Hornbrook, Christine Lu and Debra P. Ritzwoller

, or acquired, resistance (developing during imatinib treatment). 4 To overcome mutational resistance, 3 second-generation oral TKIs—dasatinib, nilotinib, and bosutinib—and 1 third-generation oral TKI, ponatinib, have received approval for use as first